Ensysce Biosciences

Update in progress

ENSC (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ensysce Biosciences is a clinical-stage pharmaceutical company focused on safer pain relief and treatment of opioid-related disorders in the United States. It uses the Trypsin Activated Abuse Protection (TAAP) platform to release drugs only under specific physiological conditions, and the Multi-Pill Abuse Resistance (MPAR) platform for overdose protection. Lead PF614 is a TAAP oxycodone prodrug; PF614-MPAR combines PF614 with nafamostat. The company also develops PF8001 and PF8026 (amphetamine prodrugs for ADHD) and PF9001 for opioid use disorder. Founded in 2003, based in La Jolla, California.

Company score

Sentiment: 0.09; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.04; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive